# Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy

> **NCT03069703** · PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 96 (actual)

## Conditions studied

- Invasive Pneumococcal Infection

## Interventions

- **BIOLOGICAL:** PCV13
- **BIOLOGICAL:** PPV23
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03069703
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-05
- **Primary completion:** 2020-11-24
- **Final completion:** 2021-11-21
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2025-11-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03069703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03069703, "Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03069703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*